Da: The Book Exchange, Macclesfield, CHESH, Regno Unito
EUR 16,03
Quantità: 1 disponibili
Aggiungi al carrelloHardcover. Condizione: Near Fine. No Jacket. 3764365951. Pictorial board hardcover, from closed pharmaceutical company library. Lending record shows this book has never been borrowed. 344 pages, index, refs, illustrated with charts, photos and diagrams. A comprehensive overview of disease-modifying antirheumatic drugs (DMARDs). The introductory general chapters deal with the chemistry of DMARDs, their use in therapy, pharmacoeconomics, and a survey of opinion leaders in the field; the following specific chapters characterize each agent with regard to mechanism of action, therapy, pharmacology, efficacy, toxicity, and monitoring. For each agent some background is given, recent developments and influence of the treatment on patients` quality of life and long-term outcomes are presented. Contents clean, tight and bright. Book.
Da: Universitätsbuchhandlung Herta Hold GmbH, Berlin, Germania
EUR 12,00
Quantità: 2 disponibili
Aggiungi al carrelloXII, 343 p. Hardcover Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Gestempelt. Progress in Inflammation Research. Sprache: Englisch.
Da: Lexington Books Inc, Idaho Falls, ID, U.S.A.
Hardcover. Condizione: Good. Good+; Contents are tight and clean; Ex-Library; Hard Cover; Birkhauser; 2005; 0.
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
EUR 70,16
Quantità: 1 disponibili
Aggiungi al carrelloHardcover. Condizione: Like New. Like NewLIKE NEW. book.
Da: Mooney's bookstore, Den Helder, Paesi Bassi
EUR 48,79
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: Very good.
Condizione: Used. pp. 728 1st Edition.
EUR 146,51
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: Used. pp. 728.
Da: Ria Christie Collections, Uxbridge, Regno Unito
EUR 174,75
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. In.
Lingua: Inglese
Editore: Birkhäuser Basel, Birkhäuser Basel, 2004
ISBN 10: 3764365951 ISBN 13: 9783764365950
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 160,49
Quantità: 1 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy.
EUR 234,94
Quantità: 2 disponibili
Aggiungi al carrelloHardcover. Condizione: Brand New. 1st edition. 343 pages. German language. 9.25x6.50x1.00 inches. In Stock.
Da: Mooney's bookstore, Den Helder, Paesi Bassi
EUR 92,81
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: Very good.
Da: Majestic Books, Hounslow, Regno Unito
EUR 157,15
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: Used. pp. 728 This item is printed on demand.
Da: preigu, Osnabrück, Germania
EUR 141,20
Quantità: 5 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. Antirheumatic Therapy: Actions and Outcomes | Richard O. Day (u. a.) | Buch | xiii | Englisch | 2004 | Springer Basel | EAN 9783764365950 | Verantwortliche Person für die EU: Springer Basel AG in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.
Lingua: Inglese
Editore: Birkhäuser Basel, Birkhäuser Basel Dez 2004, 2004
ISBN 10: 3764365951 ISBN 13: 9783764365950
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
EUR 160,49
Quantità: 1 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy.Springer Basel AG in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 364 pp. Englisch.